GELS: Gelteq Expected earnings per share growth for next year

Gelteq Limited monetizes patents for gel drug delivery systems through licensing agreements with pharmaceutical manufacturers. The price action on the GURU.Markets chart, analyzed through earnings per share (EPS) forecasts, shows that 0.00 is establishing a new level. The company's technologies target the B2B market and patients with dysphagia, while expansion into veterinary medicine and sports, supported by the FDA, strengthens customer loyalty.

Gelteq Ltd (GELS): Net earnings per share change forecast for next year from 10/30/2024 to 11/15/2026

Analytical breakdowns and data insights for company Gelteq Limited Inc (GELS)

- share price and consensus valuation forecast:

Stock Price Gelteq|GELS - Broker Consensus Forecast

- market capitalization information:

Market Valuation Gelteq Limited Inc|GELS - Value Adjusted for Debt and Cash

- book capitalization information:

Net Assets per Single Share Gelteq|GELS - Net Asset Value|Market Capitalization to Book Value Ratio gelteq.com|GELS - Aggregate Asset Value

- company total debt and liquidity indicators:

- net income and valuation ratios data:

GELS - Annual Net Income|Projected Future Earnings Gelteq Limited|GELS - Market Cap to Earnings|Future Price to Earnings Gelteq Limited|GELS - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Gelteq|GELS - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Gelteq|GELS - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months gelteq.com|GELS - Net earnings per share change in current year|Expected earnings per share growth for next year Gelteq Limited

- sales revenue and business income indicators:

GELS - Company Sales Revenue|Company Projected Revenue Gelteq Limited|GELS - Price-to-Revenue Ratio|Forward P/S Multiple GELS|GELS - Annual Revenue Growth (Last Twelve Months)

Fundamental company valuation:GELS, Gelteq Ltd

This assessment of the forward EPS trend characterizes Gelteq Limited (GELS) as a high-tech issuer within the biopharmaceutical sector. The metric measures the expected rate of change in net income by aggregating analyst earnings forecasts for the next twelve months. For Gelteq Limited, growth in this indicator depends directly on the success of licensing agreements and the dosing precision of the new gel-based drug delivery system.

Analysis of competing companies